20161122_mc2-portrait-02

Release your
full potential

Be active. Be free. Experience real-life
superior treatment with PADTM Technology based drugs.

ABOUT US

MC2 Therapeutics is a privately held clinical stage specialty pharmaceutical company engaged in dermatology and ophthalmology. Read more about MC2 Therapeutics.

Platform

Our PAD™ Technology platform is the basis of a new class of cream and eye drop offering a number of advantages in the development of new topical drugs. Read more our platform.

Pipeline

Our current pipeline is comprised of development programs in psoriasis, atopic dermatitis and dry and sensitive skin and eyes. Read more about our pipeline.

LATEST NEWS

MC2 Therapeutics to present data at the 2017 ARVO Annual Meeting highlighting the therapeutic potential of PAD® Techno.

Copenhagen, February 24th, 2017 – MC2 Therapeutics today announced that two abstracts were accepted for ...

READ FULL ARTICLE

MC2 Biotek becomes MC2 Therapeutics

MC2 Biotek, a clinical stage emerging specialty pharmaceutical company focusing on dermatology and ophthalmology, today ...

READ FULL ARTICLE

 

EMA Paediatric Committee (PDCO) granted a waiver for MC2-03 PAD™ Eye Drop

Acceptance of this waiver for the Paediatric Investigation Plan (PIP) paves the way for the ...

READ FULL ARTICLE

MC2 Biotek to present at ARVO

MC2 Biotek, a clinical stage specialty pharmaceutical company focused on the development and ...

READ FULL ARTICLE

© mc2 therapeautics 2016